izpis_h1_title_alt

From tryptophan-based amides to tertiary amines : optimization of a butyrylcholinesterase inhibitor series
ID Meden, Anže (Author), ID Knez, Damijan (Author), ID Brazzolotto, Xavier (Author), ID Nachon, Florian (Author), ID Dias, Jose (Author), ID Svete, Jurij (Author), ID Stojan, Jure (Author), ID Grošelj, Uroš (Author), ID Gobec, Stanislav (Author)

.pdfPDF - Presentation file, Download (4,55 MB)
MD5: F0C505D447C6B4AFA34CF53A546EC73A
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0223523422001507 This link opens in a new window

Abstract
Lead optimization of a series of tryptophan-based nanomolar butyrylcholinesterase (BChE) inhibitors led to tertiary amines as highly potent, achiral, sp$^3$-rich analogues with better synthetic accessibility and high selectivity over acetylcholinesterase (one to ten thousandfold). Taking it one step further, the introduction of a carbamate warhead on the well-explored reversible scaffold allowed conversion to pseudoirreversible inhibitors that bound covalently to BChE and prolonged the duration of inhibition (half-life of 14.8 h for compound 45a-carbamoylated enzyme). Additionally, N-hydroxyindole was discovered as a novel leaving group chemotype. The covalent mechanism of action was confirmed by time-dependency experiments, progress curve analysis, and indirectly by co-crystallization with the human recombinant enzyme. Two crystal structures of BChE-inhibitor complexes were solved and coupled with the supporting molecular dynamics simulations increased our understanding of the structure-activity relationship, while also providing the neccessary structural infromation for future optimization of this series. Overall, this research demonstates the high versatility and potential of this series of BChE inhibitors.

Language:English
Keywords:cholinesterase inhibitors, Alzheimer's disease, butyrylcholinesterase, carbamate, pseudoirreversible inhibition
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
FKKT - Faculty of Chemistry and Chemical Technology
MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:39 str.
Numbering:Vol. 234, art. 114248
PID:20.500.12556/RUL-140000 This link opens in a new window
UDC:615.4:54:616.894
ISSN on article:0223-5234
DOI:10.1016/j.ejmech.2022.114248 This link opens in a new window
COBISS.SI-ID:100613379 This link opens in a new window
Publication date in RUL:09.09.2022
Views:505
Downloads:83
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:European journal of medicinal chemistry
Shortened title:Eur. j. med. chem.
Publisher:Elsevier
ISSN:0223-5234
COBISS.SI-ID:25429760 This link opens in a new window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.

Secondary language

Language:Slovenian
Keywords:zaviralci holinesteraze, butirilholinesteraza, karbamat, psevdoireverzibilna inhibicija, Alzheimerjeva bolezen, farmacevtska kemija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:P1-0179
Name:Napredna organska sinteza in kataliza

Funder:ARRS - Slovenian Research Agency
Funding programme:Young Researchers

Funder:Other - Other funder or multiple funders
Funding programme:France, Ministry of Armed Forces
Project number:NBC-5-C-4210

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back